when did tirzepatide come out Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market What to Expect Before and

Beyond Weight Loss: Precision Peptide Therapy

23, 2024 (HealthDay News) -- Research has already proven that the blockbuster weight-loss drug Wegovy (semaglutide) can slash a person's odds for heart attacks and strokes, and now more data from the same trial suggests that's even true for very ill patients with heart failure

In the UKPDS cohort, the development of eGFR 300 mg/g) as the main renal outcome and the other trials addressing also eGFR-related endpoints, RRT and renal death (Table 1) [11]

to reduce cardiovascular risk in people with type 2 diabetes and heart disease

References Abdelkader NF, Elbaset MA, Moustafa PE, Ibrahim SM (2022) Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: a glucose-independent effect through AMPK signaling